InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

Current share price for ACL : $2.770 0.02 (0.73%)+

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$517 Initial Director's Interest Notice - G Horan 31 Aug 2026 6:04PM $2.780 $2.770 fallen by 0.36%
$517 Final Director's Interest Notice - M McGrath 31 Aug 2026 6:01PM $2.780 $2.770 fallen by 0.36%
$517 Notification regarding unquoted securities - ACL 31 Aug 2026 12:31PM $2.790 $2.770 fallen by 0.72%
$517 Notification regarding unquoted securities - ACL 31 Aug 2026 12:18PM $2.785 $2.770 fallen by 0.54%
$517 Notification of cessation of securities - ACL 31 Aug 2026 12:12PM $2.785 $2.770 fallen by 0.54%
$517 Ceasing to be a substantial holder 24 Aug 2026 4:42PM $2.990 $2.770 fallen by 7.36%
$517 Change in substantial holding from MUFG 21 Aug 2026 6:08PM $2.960 $2.770 fallen by 6.42%
$517 Change in substantial holding 20 Aug 2026 5:48PM $2.890 $2.770 fallen by 4.15%
$517 Ceasing to be a substantial holder 19 Aug 2026 3:17PM $2.825 $2.770 fallen by 1.95%
$517 Dividend/Distribution - ACL 17 Aug 2026 8:12AM $2.350 $2.770 risen by 17.87%
$517 FY26 financial results investor presentation 17 Aug 2026 8:08AM $2.350 $2.770 risen by 17.87%
$517 Appendix 4E and FY26 financial reports 17 Aug 2026 8:08AM $2.350 $2.770 risen by 17.87%
$517 FY26 Results Investor Webinar 10 Aug 2026 4:03PM $2.350 $2.770 risen by 17.87%
$517 Date of 2026 AGM 10 Aug 2026 1:34PM $2.345 $2.770 risen by 18.12%
$517 Becoming a substantial holder 31 Jul 2026 3:47PM $2.380 $2.770 risen by 16.39%
$517 Notification regarding unquoted securities - ACL 20 Jul 2026 1:54PM $2.350 $2.770 risen by 17.87%
$517 Change in substantial holding from MUFG 17 Jul 2026 5:22PM $2.360 $2.770 risen by 17.37%
$517 Change in substantial holding 16 Jul 2026 5:22PM $2.410 $2.770 risen by 14.94%
$517 Ceasing to be a substantial holder 13 Jul 2026 3:22PM $2.210 $2.770 risen by 25.34%
$517 Becoming a substantial holder 9 Jul 2026 4:49PM $2.220 $2.770 risen by 24.77%
$517 Ceasing to be a substantial holder 2 Jul 2026 5:33PM $2.230 $2.770 risen by 24.22%
$517 Initial Director's Interest Notice - Dr Amandeep Hansra 2 Jul 2026 10:55AM $2.225 $2.770 risen by 24.49%
$517 Notification regarding unquoted securities - ACL 29 Jun 2026 3:57PM $2.245 $2.770 risen by 23.39%
$517 Change in substantial holding from MUFG 25 Jun 2026 5:07PM $2.220 $2.770 risen by 24.77%
$517 Change in substantial holding 24 Jun 2026 3:57PM $2.135 $2.770 risen by 29.74%

1 - 25 of 1017 results

Page 1 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.